Logo.png
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
16 août 2021 16h01 HE | Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...
Final CrownBio logo.jpg
Pivotal Preclinical Oncology Platform Expands to Include New Patient-Derived Organoid Models
26 mai 2020 08h00 HE | Crown Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB)...
Final CrownBio logo.jpg
Patient-Derived Tumor Organoid Drug Development Platform Launched
17 oct. 2019 08h39 HE | Crown Bioscience
SAN DIEGO, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the...
SEngine Precision Medicine Raises $5.1 Million Series A to Advance Personalized Oncology Drug Discovery Platform
02 oct. 2019 09h00 HE | SEngine Precision Medicine
SEATTLE, Wash., Oct. 02, 2019 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, an oncology pioneer accelerating cancer drug discovery through its CLIA certified, proprietary diagnostic platform...
Final CrownBio logo.jpg
CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services
27 mars 2019 08h00 HE | Crown Bioscience
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation and...